• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

剖析睾丸癌监测中随时间推移复发风险的演变情况。

Dissecting the Evolving Risk of Relapse over Time in Surveillance for Testicular Cancer.

作者信息

Nayan Madhur, Hamilton Robert J

机构信息

Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, ON, Canada.

出版信息

Adv Urol. 2018 Feb 19;2018:7182014. doi: 10.1155/2018/7182014. eCollection 2018.

DOI:10.1155/2018/7182014
PMID:29670653
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5836309/
Abstract

Testicular cancer is the most common malignancy in young men, and the incidence is increasing in most countries worldwide. The vast majority of patients present with clinical stage I disease, and surveillance is being increasingly adopted as the preferred management strategy. At the time of diagnosis, patients on surveillance are often counselled about their risk of relapse based on risk factors present at diagnosis, but this risk estimate becomes less informative in patients that have survived a period of time without experiencing relapse. Conditional survival estimates, on the other hand, provide information on a patient's evolving risk of relapse over time. In this review, we describe the concept of conditional survival and its applications for surveillance of clinical stage I seminoma and nonseminoma germ cell tumours. These estimates can be used to tailor surveillance protocols based on future risk of relapse within risk subgroups of seminoma and nonseminoma, which may reduce the burden of follow-up for some patients, physicians, and the health care system. Furthermore, conditional survival estimates provide patients with a meaningful, evolving risk estimate and may be helpful to reassure patients and reduce potential anxiety of being on surveillance.

摘要

睾丸癌是年轻男性中最常见的恶性肿瘤,全球大多数国家的发病率都在上升。绝大多数患者初诊时为临床I期疾病,监测正日益成为首选的管理策略。在诊断时,接受监测的患者通常会根据诊断时存在的风险因素接受关于复发风险的咨询,但对于那些在一段时间内未复发存活下来的患者,这种风险估计的信息量就会减少。另一方面,条件生存估计提供了患者随时间推移复发风险演变的信息。在本综述中,我们描述了条件生存的概念及其在临床I期精原细胞瘤和非精原细胞瘤生殖细胞肿瘤监测中的应用。这些估计可用于根据精原细胞瘤和非精原细胞瘤风险亚组内未来的复发风险制定监测方案,这可能会减轻一些患者、医生和医疗保健系统的随访负担。此外,条件生存估计为患者提供了一个有意义的、不断演变的风险估计,可能有助于让患者安心,并减少接受监测的潜在焦虑。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2be6/5836309/6513649592ce/AU2018-7182014.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2be6/5836309/6513649592ce/AU2018-7182014.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2be6/5836309/6513649592ce/AU2018-7182014.001.jpg

相似文献

1
Dissecting the Evolving Risk of Relapse over Time in Surveillance for Testicular Cancer.剖析睾丸癌监测中随时间推移复发风险的演变情况。
Adv Urol. 2018 Feb 19;2018:7182014. doi: 10.1155/2018/7182014. eCollection 2018.
2
Conditional risk of relapse in patients with germ cell testicular tumors: personalizing surveillance in clinical stage 1 disease.睾丸生殖细胞肿瘤患者复发的条件风险:临床1期疾病的个性化监测
Curr Opin Urol. 2018 Sep;28(5):454-460. doi: 10.1097/MOU.0000000000000526.
3
Conditional Risk of Relapse in Surveillance for Clinical Stage I Testicular Cancer.临床Ⅰ期睾丸癌监测中的复发条件风险。
Eur Urol. 2017 Jan;71(1):120-127. doi: 10.1016/j.eururo.2016.07.013. Epub 2016 Aug 12.
4
Late Relapses in Stage I Testicular Cancer Patients on Surveillance.Ⅰ期睾丸癌患者在监测中的晚期复发。
Eur Urol. 2016 Aug;70(2):365-71. doi: 10.1016/j.eururo.2016.03.016. Epub 2016 Mar 17.
5
Treatment preferences in stage IA and IB testicular seminoma: multicenter study of Anatolian Society of Medical Oncology.IA期和IB期睾丸精原细胞瘤的治疗偏好:安纳托利亚医学肿瘤学会多中心研究
World J Urol. 2015 Oct;33(10):1613-22. doi: 10.1007/s00345-015-1492-9. Epub 2015 Jan 21.
6
[Adjuvant treatment for stage I of testicular germ cell tumours].[睾丸生殖细胞肿瘤I期的辅助治疗]
Klin Onkol. 2009;22(1):22-6.
7
A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion.一种基于胚胎性成分优势和淋巴管浸润评估的临床分期为1期的非精原细胞瘤性生殖细胞肿瘤(NSGCT)的精细风险分层方案。
Ann Oncol. 2015 Jul;26(7):1396-401. doi: 10.1093/annonc/mdv180. Epub 2015 Apr 17.
8
Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer.个性化,而非屈尊俯就:以公正呈现治疗选择的方式来维护 I 期睾丸癌患者自主权。
Ann Oncol. 2015 May;26(5):833-838. doi: 10.1093/annonc/mdu514. Epub 2014 Nov 6.
9
Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort.基于人群的队列研究:Ⅰ期非精原细胞瘤睾丸生殖细胞肿瘤的监测:结果和长期随访。
J Clin Oncol. 2014 Dec 1;32(34):3817-23. doi: 10.1200/JCO.2013.53.5831. Epub 2014 Sep 29.
10
Surveillance for stage I testicular germ cell tumours: results and cost benefit analysis of management options.I期睾丸生殖细胞肿瘤的监测:管理方案的结果及成本效益分析
Eur J Cancer. 2000 Oct;36(15):1925-32. doi: 10.1016/s0959-8049(00)00140-4.

引用本文的文献

1
Immunohistochemical expression of Nectin-4 and potential implications for enfortumab vedotin therapy in germ cell tumors of the testis: a preliminary study.Nectin-4在睾丸生殖细胞肿瘤中的免疫组化表达及其对恩沃利单抗治疗的潜在意义:一项初步研究
Virchows Arch. 2025 Sep 11. doi: 10.1007/s00428-025-04243-x.
2
Prediction of relapse in stage I testicular germ cell tumor patients on surveillance: investigation of biomarkers.I 期睾丸生殖细胞肿瘤患者监测中复发的预测:生物标志物的研究。
BMC Cancer. 2020 Aug 5;20(1):728. doi: 10.1186/s12885-020-07220-6.

本文引用的文献

1
The association between institution at orchiectomy and outcomes on active surveillance for clinical stage I germ cell tumours.睾丸切除时的医疗机构与临床I期生殖细胞肿瘤主动监测结果之间的关联。
Can Urol Assoc J. 2016 May-Jun;10(5-6):204-209. doi: 10.5489/cuaj.3513.
2
Conditional Risk of Relapse in Surveillance for Clinical Stage I Testicular Cancer.临床Ⅰ期睾丸癌监测中的复发条件风险。
Eur Urol. 2017 Jan;71(1):120-127. doi: 10.1016/j.eururo.2016.07.013. Epub 2016 Aug 12.
3
Clinical Characteristics and Outcomes of Late Relapse in Stage I Testicular Seminoma.
I期睾丸精原细胞瘤晚期复发的临床特征与结局
Clin Oncol (R Coll Radiol). 2016 Oct;28(10):648-54. doi: 10.1016/j.clon.2016.06.001. Epub 2016 Jun 20.
4
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.EAU 指南:非肌层浸润性膀胱尿路上皮癌:2016 年更新版。
Eur Urol. 2017 Mar;71(3):447-461. doi: 10.1016/j.eururo.2016.05.041. Epub 2016 Jun 17.
5
Conditional Survival of Patients With Metastatic Testicular Germ Cell Tumors Treated With First-Line Curative Therapy.一线治愈性疗法治疗转移性睾丸生殖细胞肿瘤患者的条件生存。
J Clin Oncol. 2016 Mar 1;34(7):714-20. doi: 10.1200/JCO.2015.64.7909. Epub 2016 Jan 19.
6
Guidelines on Testicular Cancer: 2015 Update.睾丸癌诊疗指南:2015 年更新版
Eur Urol. 2015 Dec;68(6):1054-68. doi: 10.1016/j.eururo.2015.07.044. Epub 2015 Aug 18.
7
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update.欧洲泌尿外科学会上尿路上皮细胞癌指南:2015 年更新版。
Eur Urol. 2015 Nov;68(5):868-79. doi: 10.1016/j.eururo.2015.06.044. Epub 2015 Jul 16.
8
EAU guidelines on renal cell carcinoma: 2014 update.EAU 指南:肾细胞癌. 2014 年更新版.
Eur Urol. 2015 May;67(5):913-24. doi: 10.1016/j.eururo.2015.01.005. Epub 2015 Jan 21.
9
Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort.基于人群的队列研究:Ⅰ期非精原细胞瘤睾丸生殖细胞肿瘤的监测:结果和长期随访。
J Clin Oncol. 2014 Dec 1;32(34):3817-23. doi: 10.1200/JCO.2013.53.5831. Epub 2014 Sep 29.
10
Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance.I期精原细胞瘤监测中复发风险的预后模型评估。
Cancer Med. 2015 Jan;4(1):155-60. doi: 10.1002/cam4.324. Epub 2014 Sep 19.